BiotechTube

darbepoetin alfa + recombinant human erythropoietin (rHuEPO)

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gynecological Malignancies

Conditions

Gynecological Malignancies, Genital Neoplasms, Female, Anemia

Trial Timeline

Oct 1, 2002 → Dec 1, 2003

NCT ID
NCT00121030

About darbepoetin alfa + recombinant human erythropoietin (rHuEPO)

darbepoetin alfa + recombinant human erythropoietin (rHuEPO) is a phase 2 stage product being developed by Amgen for Gynecological Malignancies. The current trial status is completed. This product is registered under clinical trial identifier NCT00121030. Target conditions include Gynecological Malignancies, Genital Neoplasms, Female, Anemia.

What happened to similar drugs?

0 of 1 similar drugs in Gynecological Malignancies were approved

Approved (0) Terminated (0) Active (1)
🔄Ciprofol + PropofolHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00121030Phase 2Completed
NCT00120679Phase 2Completed

Competing Products

3 competing products in Gynecological Malignancies

See all competitors
ProductCompanyStageHype Score
Durvalumab + TremelimumabAstraZenecaPhase 1
21
Vigil + AtezolizumabRochePhase 2
35
Ciprofol + PropofolHaisco Pharmaceutical GroupPhase 3
40